REGULATORY

• LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
  June 19, 2026

• MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
  June 19, 2026

• MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
  June 19, 2026

• LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
  June 19, 2026

• LDP Patch League Urges Drug Price Support as Costs Continue to Climb
  June 19, 2026

• Nippon Ishin Calls for Pharma to Be Designated Strategic Industry
  June 18, 2026

• New Chuikyo Payer Rep Wary of Blanket Inflation Adjustment for Reimbursement
  June 17, 2026

• CEA Review Group Discusses Evidence for Additional Usefulness
  June 17, 2026

• Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
  June 17, 2026

• Drug Makers Back Patent Protection for AI-Generated Inventions: JPO
  June 17, 2026

• LDP Panel Calls for Action on Women’s Health Issues in Policy Proposals
  June 17, 2026

• PMDA Flags PPI/P-CAB Drugs, Checkpoint Inhibitors, and Others in Risk Review
  June 17, 2026

• Nippon Ishin Calls for Integrated Use of Medical Data
  June 17, 2026

• Panel Questions Timing of Tavneos Blue Letter Action
  June 17, 2026

• Minister Signals Chuikyo Review of Innovation Incentives after Roadmap
  June 17, 2026

• Limas, Ezharmia Among Drugs Subject to Label Revisions
  June 17, 2026

• MHLW Issues Guidance on Proper Use of GLP-1 Drugs
  June 17, 2026

• Japan Panel Seeks Easing of Rules on Radiopharma Research Samples
  June 16, 2026

• LDP Team Reviews Draft Industry Cluster Plans for Radiopharma, Blood Products
  June 16, 2026

• DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
  June 15, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »